Boston Scientific (BSX) Short term Debt (2009 - 2026)

Boston Scientific (BSX) has 18 years of Short term Debt data on file, last reported at $41.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt fell 94.72% year-over-year to $41.0 million; the trailing twelve-month figure through Mar 2026 stood at $41.0 million (down 94.72% YoY), and the FY2025 full-year result was $299.0 million, down 83.18% from the prior year.
• Short term Debt declined to $41.0 million in Q1 2026, from $299.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $1.8 billion in Q4 2024 to a low of $20.0 million in Q3 2022.
• A 5-year average of $631.5 million and a median of $510.0 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt surged 2555.0% in 2023 and slumped 94.72% in 2026, its largest moves.
• Tracing BSX's Short term Debt over 5 years: stood at $20.0 million in 2022, then surged by 2555.0% to $531.0 million in 2023, then jumped by 234.84% to $1.8 billion in 2024, then slumped by 83.18% to $299.0 million in 2025, then slumped by 86.29% to $41.0 million in 2026.
• Business Quant data shows BSX's Short term Debt at $41.0 million in Q1 2026, $299.0 million in Q4 2025, and $483.0 million in Q3 2025.